Esbriet (pirfenidone) was rigorously analyzed in three phase 3 trials

Esbriet was evaluated in 1247 patients with IPF in three phase 3 trials 1

The efficacy of Esbriet was evaluated in three phase 3, randomized, double-blind, placebo-controlled, multicenter trials 1-3

  • Adult patients were enrolled who had a clinical and radiographic diagnosis of IPF (with or without accompanying surgical biopsy), without evidence or suspicion of an alternative diagnosis for interstitial lung disease 1
  • Study drug was administered with food in 3 equally divided doses and gradually increased to full dose over 2 weeks 2,3


Esbriet was studied across a range of patients with IPF

Clinical trials included patients with IPF with a range of clinical characteristics, select comorbidities, and concomitant medications 15

%FVC=percent predicted forced vital capacity; %DLco=percent predicted diffusing capacity of lung for carbon monoxide; FVC=forced vital capacity.
*Prevalence of comorbidities occurred in ≥15% of enrolled patients across all trials (N=1247).
Medications listed are commonly administered for select comorbidities.



Find out how Esbriet supports your patients with education and inspiration to help them get the most out of therapy


A representative is available to answer your questions about Esbriet


Learn more about the safety and tolerability profile of Esbriet